Prolo Pharmaceutical Co., Ltd. (hereinafter referred to as "the Company") announces that its holding subsidiary, Zhejiang Prolo Kangyu Pharmaceutical Co., Ltd. (hereinafter referred to as "Kangyu Pharmaceutical"), has received a drug registration certificate for Fluvastatin Sodium Sustained-Release Tablets issued by the National Medical Products Administration (hereinafter referred to as "NMPA"). The relevant details are announced as follows:
000739SZSE
Announcement on Obtaining Drug Registration Certificate
✨ AI Summary
Prolo Pharmaceutical Co., Ltd. announced that its subsidiary, Zhejiang Prolo Kangyu Pharmaceutical Co., Ltd., received a drug registration certificate for Fluvastatin Sodium Sustained-Release Tablets from the National Medical Products Administration. The product is approved for market with a specification of 80mg. This approval enhances the company's product pipeline in lipid-lowering medications and strengthens its market competitiveness.
Summary generated by AI · Always verify with source document
Full Translation
AI Translation· azure_openai
Sign in to read the full translation
Free accounts get 10 full releases per month. Pro subscribers get unlimited access.